Compare NUAI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUAI | PRTA |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.0M | 429.2M |
| IPO Year | 2024 | 2013 |
| Metric | NUAI | PRTA |
|---|---|---|
| Price | $2.72 | $8.50 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $11.67 | ★ $21.40 |
| AVG Volume (30 Days) | ★ 9.8M | 530.2K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.89 | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $885,400.00 | $814,000.00 |
| Revenue This Year | N/A | $754.03 |
| Revenue Next Year | $1,783.33 | N/A |
| P/E Ratio | ★ N/A | $34.04 |
| Revenue Growth | ★ 66.18 | N/A |
| 52 Week Low | $2.01 | $7.73 |
| 52 Week High | $9.45 | $11.80 |
| Indicator | NUAI | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 30.54 | 47.94 |
| Support Level | N/A | $8.06 |
| Resistance Level | $5.52 | $9.18 |
| Average True Range (ATR) | 0.39 | 0.39 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 7.77 | 38.35 |
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.